Last Updated: November 21, 2026

MEXITIL Drug Patent Profile

« Back to Dashboard


When do Mexitil patents expire, and what generic alternatives are available?

Mexitil is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in MEXITIL is mexiletine hydrochloride. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mexiletine hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for MEXITIL?
  • What are the global sales for MEXITIL?
  • What is Average Wholesale Price for MEXITIL?
Summary for MEXITIL
Recent Clinical Trials for MEXITIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalPhase 2
Spaulding Clinical Research LLCPhase 1
Food and Drug Administration (FDA)Phase 1

See all MEXITIL clinical trials

US Patents and Regulatory Information for MEXITIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-002 Dec 30, 1985 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-003 Dec 30, 1985 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-004 Dec 30, 1985 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MEXITIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-002 Dec 30, 1985 3,954,872 ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-003 Dec 30, 1985 4,031,244 ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-004 Dec 30, 1985 3,954,872 ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-004 Dec 30, 1985 4,031,244 ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-003 Dec 30, 1985 3,954,872 ⤷  Start Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-002 Dec 30, 1985 4,031,244 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MEXITIL

See the table below for patents covering MEXITIL around the world.

Country Patent Number Title Estimated Expiration
Austria 288353 ⤷  Start Trial
Austria 289075 ⤷  Start Trial
Austria 291225 ⤷  Start Trial
Switzerland 509250 Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminopropane (1-Phenoxy-2-aminoalkanes) ⤷  Start Trial
Switzerland 509251 Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminoalkane ⤷  Start Trial
Switzerland 509252 Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminopropane ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

MEXITIL (Mexiletine) Market Dynamics, Patent Status, and Financial Trajectory

Last updated: October 5, 2026

MEXITIL is the former brand name for mexiletine hydrochloride, an oral class IB antiarrhythmic approved in the United States for documented life-threatening ventricular arrhythmias. Its original commercial opportunity has largely ended: U.S. brand marketing is no longer the primary channel, active patent protection is not a material barrier, and generic mexiletine is available through multiple manufacturers. Current demand is concentrated in a small arrhythmia market and in off-label treatment of myotonia and related neuromuscular disorders.

No standalone revenue figure for MEXITIL or generic mexiletine is publicly reported by the principal manufacturers. The product is a low-revenue, mature generic medicine rather than a growth pharmaceutical asset.

What is MEXITIL and what is mexiletine used for?

MEXITIL is the historical brand for mexiletine hydrochloride, a sodium-channel blocker related pharmacologically to lidocaine. The U.S. label identifies mexiletine for the treatment of documented life-threatening ventricular arrhythmias, including sustained ventricular tachycardia. The label limits use to patients in whom the arrhythmia is life-threatening because of proarrhythmic and cardiac-risk considerations (U.S. Food and Drug Administration [FDA], 2023).

Mexiletine is also prescribed off label for:

  • Nondystrophic myotonia
  • Myotonic disorders
  • Myotonic dystrophy
  • Certain painful muscle stiffness syndromes
  • Selected ventricular arrhythmia cases when other therapies are unsuitable

The neuromuscular use has increased clinical interest in mexiletine, but it has not converted the product into a large commercial opportunity because the drug remains inexpensive, generic, and clinically specialized.

MEXITIL dosage forms and strengths

The conventional U.S. dosage form is an immediate-release oral capsule. FDA labeling identifies 150 mg, 200 mg, and 250 mg capsule strengths. Dosage is individualized, with the label describing an initial adult regimen commonly divided into three daily doses and a maximum generally limited by tolerability and clinical response (FDA, 2023).

Product characteristic MEXITIL / mexiletine position
Active ingredient Mexiletine hydrochloride
Drug class Class IB antiarrhythmic
Primary FDA indication Life-threatening ventricular arrhythmias
Route Oral
U.S. dosage form Immediate-release capsules
Common strengths 150 mg, 200 mg, 250 mg
Brand status Legacy brand; generic supply is the principal U.S. channel
Key off-label market Nondystrophic myotonia and related neuromuscular disorders
Biologic status Not applicable; mexiletine is a small molecule

When did MEXITIL lose exclusivity?

MEXITIL lost meaningful market exclusivity decades ago. The product was approved in the United States in the mid-1980s, and generic competition subsequently developed. The commercial market is now governed by abbreviated new drug applications rather than by a protected brand franchise.

FDA’s Orange Book is the controlling source for listed patents, exclusivity, and therapeutic-equivalence information. A current Orange Book review should be used for transaction diligence because listing status can change as products are withdrawn, discontinued, or removed from active marketing. For a mature product such as mexiletine, no active composition-of-matter or core formulation patent should be expected to block generic entry (FDA, 2024a).

MEXITIL patent expiration and exclusivity timeline

Event Approximate timing Commercial effect
Original U.S. approval 1980s Brand launch for ventricular arrhythmias
Core patent term Expired before the current generic market No durable patent barrier
Generic entry Following expiration of original exclusivity Price competition and brand erosion
Current market Generic-dominated Limited pricing power
New clinical interest 2000s onward Off-label neuromuscular demand, without new product exclusivity

No meaningful current revenue protection is associated with the historical MEXITIL brand. Any patent claims that once covered mexiletine, its manufacture, or its oral dosage form would be expected to have expired based on the age of the product.

What is the Orange Book status of MEXITIL?

MEXITIL should be analyzed as a legacy branded product with generic competition rather than as an actively protected innovator medicine. The Orange Book distinguishes approved products, therapeutic-equivalence ratings, patent listings, and marketing status. Generic mexiletine capsules may be listed under separate ANDAs even when the original brand is discontinued or no longer commercially significant (FDA, 2024a).

The key Orange Book diligence points are:

  1. Whether the original MEXITIL NDA remains listed as actively marketed.
  2. Whether any branded product has been discontinued.
  3. Which mexiletine ANDAs are listed as therapeutically equivalent.
  4. Whether any patent or exclusivity entry remains attached to an active product.
  5. Whether the reference-listed drug status creates a regulatory, rather than patent, constraint.

For business purposes, the distinction between FDA approval and active commercial supply matters. An NDA can remain part of the regulatory record even when the brand has little or no current revenue.

How many patents cover mexiletine?

The commercially relevant patent count is effectively zero for blocking exclusivity on the active ingredient. Mexiletine is an old small-molecule compound, and the foundational patents would have expired long before the current market.

Potential residual IP categories include:

  • Process patents for manufacturing or purification
  • Salt, polymorph, or solid-state claims
  • Formulation claims
  • Combination-product claims
  • Method-of-use claims for neuromuscular disorders
  • Device or delivery claims, if a new presentation is developed

These categories do not appear to create a broad barrier around conventional generic mexiletine capsules. A new patent could matter only if it covered a commercially differentiated product, such as an extended-release formulation, a novel dosage form, or a new FDA-approved indication.

What formulations are protected by mexiletine patents?

The standard immediate-release capsule is a mature formulation. Its low technical complexity reduces the likelihood that formulation IP can support sustained premium pricing. A differentiated product could pursue:

  • Extended-release oral delivery
  • Improved gastrointestinal tolerability
  • Lower peak plasma concentrations
  • Modified dosing frequency
  • Pediatric liquid formulations
  • Neuromuscular-disease-specific dosing systems

A new formulation would still face a market challenge: physicians and patients can often substitute low-cost immediate-release generic capsules unless the new product demonstrates clear clinical or adherence benefits.

Is mexiletine protected by method-of-use patents?

Method-of-use protection is more plausible than composition-of-matter protection, but its commercial value is limited without a corresponding FDA-approved label and enforceable prescribing behavior.

Mexiletine’s most commercially relevant non-arrhythmia use is treatment of myotonia. Randomized clinical evidence has supported its use in nondystrophic myotonia, and professional practice has expanded beyond the original ventricular-arrhythmia indication (Statland et al., 2012). That clinical use does not automatically create market exclusivity.

A method-of-use patent could face several limitations:

  • Off-label use is legally available to physicians.
  • Generic manufacturers can seek approval for the original indication.
  • Label carve-outs may reduce infringement exposure.
  • Payers may reimburse the generic product without recognizing a separate protected use.
  • The patient population is small relative to major neurologic markets.

The strongest commercial opportunity would require a new FDA-approved indication paired with a proprietary formulation or a legally enforceable use patent. Conventional generic mexiletine does not have that profile.

What is the FDA regulatory status of MEXITIL?

The FDA-approved use of mexiletine remains treatment of documented life-threatening ventricular arrhythmias. The prescribing information warns about mortality risk, proarrhythmia, hepatic effects, neurologic adverse events, and gastrointestinal intolerance (FDA, 2023).

FDA regulatory considerations include:

  • The drug is approved as a small-molecule oral product.
  • Generic versions can be approved through ANDAs.
  • No biosimilar pathway applies.
  • New formulations may require an ANDA suitability determination, a 505(b)(2) application, or a full NDA, depending on the extent of the change.
  • A new indication could require supplemental clinical evidence or a separate approval strategy.

The regulatory burden for a new mexiletine product is therefore moderate for a conventional generic and substantially higher for a differentiated formulation or new indication.

Which companies are challenging MEXITIL’s market?

The principal competitive pressure comes from generic manufacturers rather than from a branded challenger. FDA’s Drugs@FDA and Orange Book databases identify approved products and applicants, while commercial availability depends on manufacturer decisions, wholesalers, and contract supply arrangements (FDA, 2024a; FDA, 2024b).

The market typically includes:

  • Generic capsule manufacturers
  • Contract manufacturers
  • Specialty pharmacies
  • Hospital and institutional suppliers
  • Compounding pharmacies in limited circumstances

The specific active supplier set can change. Generic markets with low annual volume often experience periodic manufacturer exits, back-ordering, or wholesaler concentration. That can produce temporary price increases even when long-term patent protection is absent.

What patent litigation and Paragraph IV risk affect mexiletine?

No major current Paragraph IV litigation campaign is associated with the legacy MEXITIL product. The reason is structural: the core product is old, the principal dosage form is conventional, and generic entry has already occurred.

A Paragraph IV dispute could arise if a company launched a new protected formulation or obtained patents covering a new indication. Potential litigation would then focus on:

  • Patent validity
  • Obviousness
  • Written description and enablement
  • Infringement by a proposed label
  • Regulatory carve-outs
  • Patent-listing eligibility in the Orange Book

For the existing immediate-release capsule market, generic launch risk is low from a patent perspective because the primary risk has already materialized through established generic competition.

How strong is the MEXITIL patent estate?

The patent estate is weak as a commercial defense for conventional mexiletine capsules. Its main strengths and weaknesses are:

Factor Assessment
Composition-of-matter protection Exhausted
Core product exclusivity Exhausted
Immediate-release capsule protection Weak or absent as a market barrier
Method-of-use protection Potentially narrow and difficult to monetize
Manufacturing IP Possible, but unlikely to block routine generic supply
New formulation opportunity Technically possible, commercially uncertain
Biosimilar protection Not applicable
Litigation deterrence Low

The product could support a niche reformulation strategy, but it does not support an ordinary brand-defense strategy.

What is the financial trajectory for MEXITIL and mexiletine?

MEXITIL’s financial trajectory is consistent with an old generic medicine:

  1. Brand-led revenue during the protected period.
  2. Rapid erosion after generic entry.
  3. Low and fragmented generic revenue.
  4. Periodic price volatility caused by supply concentration.
  5. Stable but limited demand from arrhythmia and neuromuscular prescribing.
  6. Potential niche upside from a reformulation or approved neuromuscular indication.

Manufacturers do not generally report mexiletine revenue as a separate line item. As a result, product-level sales, gross margin, and market share cannot be reliably attributed from public company filings.

Revenue exposure by market segment

Segment Commercial profile Revenue outlook
Life-threatening ventricular arrhythmias Established but small patient population Stable, low growth
Nondystrophic myotonia Specialty and largely off label Potential volume growth, limited pricing power
Myotonic dystrophy Specialist-driven use Small, uncertain
Hospital use Episodic and formulary-dependent Limited
Consumer retail generic Price-sensitive Low margin
New formulation Unproven Highest upside, highest development risk

The most important financial variable is not total demand but supply structure. A small number of active manufacturers can produce temporary price expansion, while new entrants can quickly compress prices.

How does MEXITIL compare with competing antiarrhythmics?

Mexiletine competes with other antiarrhythmics and with nonpharmacologic interventions. Its use is constrained by safety, tolerability, and the availability of alternatives.

Therapy Position relative to mexiletine
Amiodarone Broad antiarrhythmic use; substantial long-term toxicity concerns
Lidocaine Intravenous class IB comparator, mainly acute care
Sotalol Alternative for selected rhythm disorders; QT-prolongation risk
Flecainide Used in selected arrhythmias; structural-heart-disease limitations
Catheter ablation Competes in appropriate ventricular and atrial rhythm settings
Mexiletine Oral class IB option with niche use in ventricular arrhythmia and myotonia

Mexiletine’s differentiation is practical rather than proprietary. It offers oral sodium-channel blockade and has clinical utility in disorders where alternatives may be poorly tolerated or ineffective. That value does not translate into strong pricing power.

What generic entry risks exist?

For an investor or licensing party, generic entry risk is already realized rather than prospective. The relevant risks are:

  • Continued price compression
  • Manufacturer withdrawal
  • Product shortages
  • Limited supplier redundancy
  • Substitution by other antiarrhythmics
  • Clinical reluctance caused by adverse-event warnings
  • Failure to obtain an approved neuromuscular indication
  • Inability to differentiate a new formulation

A new branded mexiletine product would need to solve a specific clinical problem. A standard capsule with ordinary labeling would face weak reimbursement and rapid generic substitution.

What licensing deals involve MEXITIL?

No major current licensing transaction is publicly associated with MEXITIL as a growth asset. Historical rights may have moved among pharmaceutical companies during the product’s commercial life, but the legacy brand is not generally treated as a separately disclosed strategic franchise.

A potentially financeable licensing opportunity would more likely involve:

  • A sustained-release formulation
  • A pediatric presentation
  • A product for nondystrophic myotonia
  • A combination with diagnostic or monitoring services
  • Rights in a geography with limited generic competition

The absence of active core patents makes territorial licensing less valuable unless the license includes a differentiated formulation, regulatory approval, manufacturing advantage, or market access position.

What is the geographic coverage of mexiletine?

Mexiletine has been marketed in multiple jurisdictions under different brand and generic names, but regulatory status and commercial supply vary by country. The international opportunity is constrained by:

  • Local generic competition
  • National reimbursement controls
  • Different antiarrhythmic treatment guidelines
  • Product-registration requirements
  • Distribution economics
  • Local shortages and procurement practices

U.S. patent expiration does not determine freedom to operate in Europe, Japan, Canada, or emerging markets. Each jurisdiction requires separate review of patent registers, marketing authorizations, and local exclusivity rules.

Key Takeaways

  • MEXITIL is the legacy brand for mexiletine hydrochloride.
  • The FDA-approved indication is documented life-threatening ventricular arrhythmias.
  • Generic mexiletine capsules are the principal U.S. commercial products.
  • Foundational patent and exclusivity protection have expired.
  • No active patent estate is expected to block conventional generic entry.
  • Off-label neuromuscular use creates clinical interest but not automatic exclusivity.
  • Product-level revenue is not separately disclosed by major manufacturers.
  • The financial profile is low-volume, generic, and supply-sensitive.
  • The main commercial opportunity would require a differentiated formulation or new approved indication.
  • The main risks are price compression, supplier concentration, shortages, and limited reimbursement leverage.

Frequently Asked Questions

Is MEXITIL still available in the United States?

The legacy brand is not the principal U.S. supply channel. Mexiletine hydrochloride is available primarily through generic capsule products, subject to manufacturer and wholesaler inventory.

Is mexiletine a controlled substance?

Mexiletine is not generally classified as a controlled substance under the U.S. Controlled Substances Act. It remains a prescription antiarrhythmic requiring clinical monitoring.

Can a generic manufacturer launch mexiletine without a license from the original MEXITIL sponsor?

Yes. Generic manufacturers can pursue FDA approval through the ANDA pathway when applicable patents and exclusivity have expired or are otherwise nonblocking.

Does mexiletine have orphan-drug exclusivity for myotonia?

Clinical use in myotonia does not by itself establish orphan-drug exclusivity. Exclusivity would require a qualifying FDA designation and approval for the relevant indication.

Could an extended-release mexiletine product support premium pricing?

Potentially, but only if it improves adherence, tolerability, or clinical outcomes enough to justify reimbursement against low-cost immediate-release generic capsules.

References

  1. U.S. Food and Drug Administration. (2023). Mexiletine hydrochloride capsules: Prescribing information.
  2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  3. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database.
  4. Statland, J. M., Bundy, B. N., Wang, Y., Rayan, D. R., Trivedi, J. R., Sansone, V. A., Salajegheh, M. K., McDermott, M. P., Herbelin, L. L., Griffin, J. M., Jeffrey, I., Pucillo, E. M., McVey, A. L., & Tawil, R. (2012). Mexiletine is an effective antimyotonia treatment in nondystrophic myotonia: A randomized, double-blind, placebo-controlled trial. Annals of Neurology, 72(6), 895-902.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.